Endari approved for treatment of sickle cell disease

The U.S. Food and Drug Administration today approved Endari (L-glutamine oral powder) for patients age five years and older with sickle cell disease to reduce severe complications associated with the blood disorder. "Endari is the first treatment approved for patients with sickle cell disease in almost 20 years," said Richard Pazdur, M.D., acting director of ["]

The post Endari approved for treatment of sickle cell disease appeared first on Outbreak News Today.